AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...

Researchers have identified a protein, TMEM16F, that appears to aid the spread of Parkinson’s pathology in the brain.

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Nir Giladi from TAU’s Faculty of Medical and Health Sciences and the Tel Aviv Sourasky Medical Center, as well as other researchers from TAU and the University of Haifa. The study was backed by the ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's ... in the TMEM16F gene that ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

The following column was originally published on Feb. 25, 2022. Thanks to breakthroughs in medicine and nutrition in recent years, we are living longer than ever before. But this increase in life ...

These include people in group living settings and those at risk of more severe disease or outcomes. Following individual public health measures helps to protect these populations. Following individual ...

Parkinson disease (PD) status is not independently associated with skin tumors and no interactions have been found between PD status and cutaneous malignant melanoma (CMM) risk factors, according to ...

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...

Research examined medical records from over one million people to uncover early indicators of the incurable condition.